Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MMP12 | P39900 | 1/20 | 0.63 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | ABAT | P80404 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4829970 | 0.88 | MMP1 (0.67) | MMP1GAAMMP12CA1CA2 | |
| SCHEMBL7673748 | 0.82 | ALDH1A1 (0.74) | MMP1GAAMMP12ALDH1A1LMNA | |
| SCHEMBL4834530 | 0.82 | LMNA (0.74) | MMP1GAAMMP12ALDH1A1CA1 | |
| SCHEMBL359770 | 0.81 | MMP1 (0.79) | MMP1GAAMMP12ALDH1A1 | |
| SCHEMBL4824728 | 0.80 | POLB (0.73) | MMP1GAAMMP12ALDH1A1CA1 | |
| SCHEMBL25132370 | 0.80 | ALDH1A1 (0.71) | ALDH1A1CA1CA2LMNA | |
| SCHEMBL4828109 | 0.80 | PRMT1 (0.69) | MMP1GAAMMP12CA1CA2 | |
| SCHEMBL3396831 | 0.80 | ALDH1A1 (0.85) | GAAPTPN7ALDH1A1LMNAMAPT | |
| SCHEMBL14534186 | 0.79 | MMP1 (0.71) | MMP1GAAMMP12ALDH1A1LMNA | |
| SCHEMBL7668894 | 0.79 | MMP1 (0.58) | MMP1GAAMMP12ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6403644-B1 | FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-06-11 | — | — | US | claimed |
| EP-0757037-A2 | Sulfonylamino acid derivatives as metalloproteinase inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 1997-02-05 | — | — | EP | claimed |
| US-7335686-B2 | Method and composition for treating osteoporosis | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2008-02-26 | — | — | US | disclosed |
| EP-1678124-A1 | NOVEL MOLECULES TO DEVELOP DRUG FOR THE TREATMENT OF OSTEOPOROSIS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005037774-A1 | NOVEL MOLECULES TO DEVELOP DRUG FOR THE TREATMENT OF OSTEOPOROSIS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-04-28 | — | — | WO | disclosed |
| US-20050085537-A1 | Method and composition for treating osteoporosis | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085537-A1 | Method and composition for treating osteoporosis | SOST, CALCR, MSR1 | MMP1 2084/4885GAA 4390/4885MMP12 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.